Trial Profile
A Phase Ib Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs LCL 161 (Primary) ; Paclitaxel
- Indications Advanced breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 26 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Aug 2014 Planned End Date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 21 Aug 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.